Literature DB >> 23160949

Recombinant single-chain antibody with the Trojan peptide penetratin positioned in the linker region enables cargo transfer across the blood-brain barrier.

Nives Skrlj1, Gorazd Drevenšek, Samo Hudoklin, Rok Romih, Vladka Curin Šerbec, Marko Dolinar.   

Abstract

Delivery of therapeutic proteins into tissues and across the blood-brain barrier (BBB) is limited by the size and biochemical properties of the proteins. Efficient delivery across BBB is generally restricted to small, highly lipophilic molecules. However, in the last decades, several peptides that can pass cell membranes have been identified. It has been shown that these peptides are also capable of delivering large hydrophilic cargoes into cells and are therefore a powerful biological tool for transporting drugs across cell membranes and even into the brain. We designed and prepared a single-chain antibody fragment (scFvs), specific for the pathological form of the prion protein (PrP(Sc)), where a cell-penetrating peptide (CPP) was used as a linker between the two variable domains of the scFv. The intravenously administered recombinant scFv-CPP was successfully targeted to and delivered into mouse brain cells. Our single-chain antibody fragments are of special interest in view of possible therapeutic reagents design not only for prion diseases but also for other neurodegenerative diseases.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23160949     DOI: 10.1007/s12010-012-9962-7

Source DB:  PubMed          Journal:  Appl Biochem Biotechnol        ISSN: 0273-2289            Impact factor:   2.926


  14 in total

1.  New engineered antibodies against prions.

Authors:  Nives Škrlj; Marko Dolinar
Journal:  Bioengineered       Date:  2013-08-09       Impact factor: 3.269

Review 2.  Gene-based antibody strategies for prion diseases.

Authors:  Alessio Cardinale; Silvia Biocca
Journal:  Int J Cell Biol       Date:  2013-08-21

Review 3.  Prion protein-specific antibodies-development, modes of action and therapeutics application.

Authors:  Tihana Lenac Rovis; Giuseppe Legname
Journal:  Viruses       Date:  2014-10-01       Impact factor: 5.048

4.  Characterization of four new monoclonal antibodies against the distal N-terminal region of PrP(c).

Authors:  Alessandro Didonna; Anja Colja Venturini; Katrina Hartman; Tanja Vranac; Vladka Čurin Šerbec; Giuseppe Legname
Journal:  PeerJ       Date:  2015-03-19       Impact factor: 2.984

5.  α-synuclein conformational antibodies fused to penetratin are effective in models of Lewy body disease.

Authors:  Brian Spencer; Stephanie Williams; Edward Rockenstein; Elvira Valera; Wei Xin; Michael Mante; Jazmin Florio; Anthony Adame; Eliezer Masliah; Michael R Sierks
Journal:  Ann Clin Transl Neurol       Date:  2016-06-16       Impact factor: 4.511

6.  Fibrillar form of α-synuclein-specific scFv antibody inhibits α-synuclein seeds induced aggregation and toxicity.

Authors:  Vijay Gupta; Safa Salim; Issam Hmila; Nishant N Vaikath; Indulekha P Sudhakaran; Simona S Ghanem; Nour K Majbour; Sara A Abdulla; Mohamed M Emara; Houari B Abdesselem; Tamas Lukacsovich; Daniel Erskine; Omar M A El-Agnaf
Journal:  Sci Rep       Date:  2020-05-18       Impact factor: 4.379

Review 7.  Single-chain fragment variable passive immunotherapies for neurodegenerative diseases.

Authors:  Liang Huang; Xiaomin Su; Howard J Federoff
Journal:  Int J Mol Sci       Date:  2013-09-17       Impact factor: 5.923

Review 8.  Nanoscale drug delivery systems and the blood-brain barrier.

Authors:  Renad Alyautdin; Igor Khalin; Mohd Ismail Nafeeza; Muhammad Huzaimi Haron; Dmitry Kuznetsov
Journal:  Int J Nanomedicine       Date:  2014-02-07

Review 9.  Recombinant Antibody Fragments for Neurodegenerative Diseases.

Authors:  Karen Manoutcharian; Roxanna Perez-Garmendia; Goar Gevorkian
Journal:  Curr Neuropharmacol       Date:  2017       Impact factor: 7.363

Review 10.  Targeting Malignant Brain Tumors with Antibodies.

Authors:  Rok Razpotnik; Neža Novak; Vladka Čurin Šerbec; Uros Rajcevic
Journal:  Front Immunol       Date:  2017-09-25       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.